^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Source:
Title:

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

Excerpt:
The patient was a boy aged 15 months at the time of enrollment with a phosphodiesterase 4D‐interacting protein (PDE4DIP)–NTRK1 fusion, localized, intramuscular soft‐tissue sarcoma…The patient received 2 cycles of ifosfamide and etoposide. She had an inadequate response and subsequently initiated treatment with larotrectinib. She achieved a confirmed partial response with a 93% reduction in tumor burden and was referred for surgery after 14 cycles of larotrectinib.
DOI:
10.1002/cncr.31701
Trial ID: